The overall theme of this proposal is the correlation of structural features of Class II molecules with their role in cell surface expression of Ia. The approach chosen is the molecular and functional analysis of Class II mutant B lymphoma cell lines produced by immunoselection on the basis of cell-surface expression or the transfection of in situ mutagenized Class II genes into Ia-negative B lymphoma cells or into non-lymphoid cells. Ia variant cell lines which have structural defects which result in the complete lack of expression of cell surface Ia despite the presence of intracytoplasmic Ia polypeptides will be used to identify sites in the Class II genes key for post-transcriptional and post-translational regulation of Class II gene expression. These cell lines will be analyzed by two dimensional gel electrophoresis, immunoelectronmicroscopy and DNA sequencing of the relevant mutant gene. Site-directed mutagenesis and recombinant DNA technology will be used to produce Class II molecules which have truncated cytoplasmic regions. These tailless mutants will be used to examine the role of the cytoplasmic domain of the Ia in chain-pairing, assembly, transport, association with invariant chain and transmembrane signalling. The role of the invariant chain in cell surface expression of Ia will be examined by the production and analysis of invariant chain molecules with truncated cytoplasmic and transmembrane regions by site directed mutagenesis to determine whether the targeting and transport of Ii affects the transport and expression of Ia. Exon- shuffling experiments between the Ii gene and the Class I Q10 gene will be performed to map the sites on Ii which mediate the contact between Ii and Ia. The central theme of this proposal, therefore, is the identification, by a mutational approach, of structural features of Class II genes including the Ii gene which affect the expression of these proteins at the post-translational level.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI021569-07
Application #
3131761
Study Section
Allergy and Immunology Study Section (ALY)
Project Start
1984-01-01
Project End
1992-06-30
Budget Start
1990-09-01
Budget End
1991-08-31
Support Year
7
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Harvard University
Department
Type
Schools of Public Health
DUNS #
082359691
City
Boston
State
MA
Country
United States
Zip Code
02115
Erlebacher, A (2001) Why isn't the fetus rejected? Curr Opin Immunol 13:590-3
de Bont, E S; Reilly, C R; Lo, D et al. (1999) A minimal level of MHC class II expression is sufficient to abrogate autoreactivity. Int Immunol 11:1295-306
Laufer, T M; Fan, L; Glimcher, L H (1999) Self-reactive T cells selected on thymic cortical epithelium are polyclonal and are pathogenic in vivo. J Immunol 162:5078-84
Laufer, T M; Glimcher, L H; Lo, D (1999) Using thymus anatomy to dissect T cell repertoire selection. Semin Immunol 11:65-70
Laufer, T M; Smiley, S T; Ranger, A et al. (1997) Single amino acid mutations in the murine MHC class II A beta cytoplasmic domain abrogate antigen presentation. J Immunol 159:5914-20
Tarleton, R L; Grusby, M J; Postan, M et al. (1996) Trypanosoma cruzi infection in MHC-deficient mice: further evidence for the role of both class I- and class II-restricted T cells in immune resistance and disease. Int Immunol 8:13-22
Zhao, J; Freeman, G J; Gray, G S et al. (1996) A cell type-specific enhancer in the human B7.1 gene regulated by NF-kappaB. J Exp Med 183:777-89
Steele, D J; Laufer, T M; Smiley, S T et al. (1996) Two levels of help for B cell alloantibody production. J Exp Med 183:699-703
Chakkalath, H R; Theodos, C M; Markowitz, J S et al. (1995) Class II major histocompatibility complex-deficient mice initially control an infection with Leishmania major but succumb to the disease. J Infect Dis 171:1302-8
Kuchroo, V K; Das, M P; Brown, J A et al. (1995) B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80:707-18

Showing the most recent 10 out of 41 publications